Merck Receives EU CHMP Opinion For KEYTRUDA As Adjuvant Treatment For Adults With Non-small Cell Lung Cancer At High Risk Of Recurrence Following Complete Resection And Platinum-Based Chemotherapy
Portfolio Pulse from Benzinga Newsdesk
Merck has received a positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) for its drug KEYTRUDA. The drug is intended as an adjuvant treatment for adults with non-small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy. The opinion was granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial.
September 15, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has received a positive opinion from the EU's CHMP, potentially opening up a new market for the drug. This could lead to increased revenues for Merck.
The positive opinion from the EU's CHMP for Merck's KEYTRUDA indicates a potential expansion of the drug's market. This could lead to increased sales and revenues for Merck, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100